Rare pediatric disease dataset license by Michele Gunness receives Deal of Distinction Award

Michele Gunness, Ph.D.

Michele Gunness, Ph.D., has been recognized for her role in a creative technology licensing deal for a rare pediatric disease dataset. The deal resulted in Fast Track Designation and Rare Pediatric Disease Designation by the FDA for the treatment of long-chain fatty acid oxidation disorders.

Unlike traditional licensing models, the intellectual property in this deal was a limited data set from 32 subjects with a fatty acid oxidation disorder. There are approximately 2,500 patients in the U.S. with these disorders.

OHSU School of Medicine researchers Melanie B. Gillingham, Ph.D., and Cary O. Harding, M.D., conducted the largest investigator-initiated clinical trial in fatty acid oxidation disorders and the only double-blind randomized trial in the field. The FDA-funded trial was conducted at OHSU and the University of Pittsburgh.

The deal negotiated by Gunness among OHSU, the University of Pittsburgh, and Ultragenyx Pharmaceutical brings together the assets and talents of academic medical centers and a biomedical company.

The 2019 Deal of Distinction Award for the Industry-University-Government Interface Sector was given to Gunness, senior technology development manager at OHSU Technology Transfer, by the Licensing Executives Society at the LES Annual Meeting Award Luncheon, Oct. 21.

3 responses to “Rare pediatric disease dataset license by Michele Gunness receives Deal of Distinction Award

  1. Congratulations Michele! Your contributions to OHSU Technology Transfer and the mission of OHSU are greatly appreciated. Thank you for your hard work and all of your efforts to ensure that the benefits of OHSU’s research is fully realized by the public.

  2. Hi Brad, it was selected as a “Deal of Distinction” not for innovation, but for serving as a good example of a licensing deal that recognizes a dataset as intellectual property. That’s a shift in how people see datasets and what might constitute IP.

Comments are closed.